Compare Ascendis Pharma A/S (ASND) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Booz Allen Hamilton Holding Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Booz Allen Hamilton Holding Corporation trades at $63.6 (market cap $7.53B). The key difference: Ascendis Pharma A/S is far larger — about 2.4× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.76% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BAH | |
|---|---|---|
Market Cap | $17.74B | $7.53B |
Sector | Health | Industrials |
52-Week High | $277.18 | $115.95 |
52-Week Low | $163.32 | $59.71 |
Enterprise Value | $18.11B | $10.92B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Booz Allen Hamilton (BAH) trades at $62.76, down 0.63% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.1 and robust profitability, including an 80.17% ROE. Recent earnings have mostly beaten estimates, and the company announced a partnership with OpenAI to advance AI in national security. Cash flow from operations improved to $1.01B in 2025, though net cash flow turned negative in 2026 projections.
BAH presents a compelling value opportunity with solid earnings growth and a consensus price target of $80.80, implying significant upside. Risks include persistent civil segment weakness noted in guidance and rising debt-to-asset ratios. Investor sentiment is mixed, with nearly half of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
